pamidronate has been researched along with tipifarnib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abbruzzese, A; Budillon, A; Caraglia, M; Colao, A; D'Alessandro, AM; Giuberti, G; Marra, M; Prete, SD; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C; Vitale, G | 1 |
1 other study(ies) available for pamidronate and tipifarnib
Article | Year |
---|---|
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Topics: Alkyl and Aryl Transferases; Apoptosis; Caspases; Cell Division; Diphosphonates; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; Farnesyltranstransferase; Humans; Imidazoles; KB Cells; Mitogen-Activated Protein Kinases; Pamidronate; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; Zoledronic Acid | 2004 |